An aberrant metabolism of apolipoprotein B-containing lipoproteins and their remnants is reported in CKD, emphasizing the potential significance of monitoring apolipoprotein B levels in assessing cardiovascular mortality and morbidity, especially in end-stage renal disease (ESRD). This evidence concerns the gene APOB and chronic kidney disease.